237 related articles for article (PubMed ID: 33740187)
21. Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations.
Iiizumi S; Ohtake J; Murakami N; Kouro T; Kawahara M; Isoda F; Hamana H; Kishi H; Nakamura N; Sasada T
Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30813491
[TBL] [Abstract][Full Text] [Related]
22. NEPdb: A Database of T-Cell Experimentally-Validated Neoantigens and Pan-Cancer Predicted Neoepitopes for Cancer Immunotherapy.
Xia J; Bai P; Fan W; Li Q; Li Y; Wang D; Yin L; Zhou Y
Front Immunol; 2021; 12():644637. PubMed ID: 33927717
[TBL] [Abstract][Full Text] [Related]
23. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
24. Generation of novel complete HLA class I monoallelic cell lines used in an MHC stabilization assay for neoantigen evaluation.
Iizuka A; Akiyama Y; Sakura N; Kanematsu A; Kikuchi Y; Nagashima T; Urakami K; Shimoda Y; Ohshima K; Shiomi A; Ohde Y; Terashima M; Uesaka K; Mukaigawa T; Hirashima Y; Yoshikawa S; Katagiri H; Sugino T; Takahashi M; Kenmotsu H; Yamaguchi K
Oncol Lett; 2023 Aug; 26(2):324. PubMed ID: 37415627
[TBL] [Abstract][Full Text] [Related]
25. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
[TBL] [Abstract][Full Text] [Related]
26. T cell receptors employ diverse strategies to target a p53 cancer neoantigen.
Wu D; Gowathaman R; Pierce BG; Mariuzza RA
J Biol Chem; 2022 Mar; 298(3):101684. PubMed ID: 35124005
[TBL] [Abstract][Full Text] [Related]
27. GNIFdb: a neoantigen intrinsic feature database for glioma.
Li W; Sun T; Li M; He Y; Li L; Wang L; Wang H; Li J; Wen H; Liu Y; Chen Y; Fan Y; Xin B; Zhang J
Database (Oxford); 2022 Feb; 2022():. PubMed ID: 35150127
[TBL] [Abstract][Full Text] [Related]
28. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
[TBL] [Abstract][Full Text] [Related]
29. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.
Molvi Z; Klatt MG; Dao T; Urraca J; Scheinberg DA; O'Reilly RJ
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775115
[TBL] [Abstract][Full Text] [Related]
30. Best practices for bioinformatic characterization of neoantigens for clinical utility.
Richters MM; Xia H; Campbell KM; Gillanders WE; Griffith OL; Griffith M
Genome Med; 2019 Aug; 11(1):56. PubMed ID: 31462330
[TBL] [Abstract][Full Text] [Related]
31. Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction.
Müller M; Huber F; Arnaud M; Kraemer AI; Altimiras ER; Michaux J; Taillandier-Coindard M; Chiffelle J; Murgues B; Gehret T; Auger A; Stevenson BJ; Coukos G; Harari A; Bassani-Sternberg M
Immunity; 2023 Nov; 56(11):2650-2663.e6. PubMed ID: 37816353
[TBL] [Abstract][Full Text] [Related]
32. T cells discriminate between groups C1 and C2 HLA-C.
Sim MJW; Stotz Z; Lu J; Brennan P; Long EO; Sun PD
Elife; 2022 May; 11():. PubMed ID: 35587797
[TBL] [Abstract][Full Text] [Related]
33. TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis.
Wu J; Zhao W; Zhou B; Su Z; Gu X; Zhou Z; Chen S
Genomics Proteomics Bioinformatics; 2018 Aug; 16(4):276-282. PubMed ID: 30223042
[TBL] [Abstract][Full Text] [Related]
34. Identification of neoantigens in oesophageal adenocarcinoma.
Nicholas B; Bailey A; McCann KJ; Wood O; Walker RC; Parker R; Ternette N; Elliott T; Underwood TJ; Johnson P; Skipp P
Immunology; 2023 Mar; 168(3):420-431. PubMed ID: 36111495
[TBL] [Abstract][Full Text] [Related]
35. Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations.
Choi J; Goulding SP; Conn BP; McGann CD; Dietze JL; Kohler J; Lenkala D; Boudot A; Rothenberg DA; Turcott PJ; Srouji JR; Foley KC; Rooney MS; van Buuren MM; Gaynor RB; Abelin JG; Addona TA; Juneja VR
Cell Rep Methods; 2021 Sep; 1(5):100084. PubMed ID: 35474673
[TBL] [Abstract][Full Text] [Related]
36. Determinants for Neoantigen Identification.
Garcia-Garijo A; Fajardo CA; Gros A
Front Immunol; 2019; 10():1392. PubMed ID: 31293573
[TBL] [Abstract][Full Text] [Related]
37. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
Sun Z; Chen F; Meng F; Wei J; Liu B
Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
[TBL] [Abstract][Full Text] [Related]
38. Neodb: a comprehensive neoantigen database and discovery platform for cancer immunotherapy.
Wu T; Chen J; Diao K; Wang G; Wang J; Yao H; Liu XS
Database (Oxford); 2023 Jun; 2023():. PubMed ID: 37311149
[TBL] [Abstract][Full Text] [Related]
39. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
40. Neoantigen vaccine: an emerging tumor immunotherapy.
Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
